Clinical Takeaway
In this pilot randomized controlled trial of 20 adults with diagnosed insomnia, a single oral dose of 10 mg THC combined with 200 mg CBD actually reduced total sleep time by approximately 24.5 minutes compared to placebo. These findings caution against assuming that cannabinoids reliably improve objective sleep outcomes, even when patients subjectively report benefit. Clinicians should recognize that high-dose CBD combined with THC may not produce the sleep-enhancing effects many patients expect, and that rigorous EEG-based evidence remains limited.
#8 Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.
Citation: Suraev Anastasia et al.. Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.. Journal of sleep research. 2026. PMID: 40631525.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
This pilot study provides the first high-resolution neurophysiological characterization of how a commonly used THC/CBD formulation acutely affects sleep architecture and cortical activity in patients with clinically diagnosed insomnia, filling a critical gap between popular patient use and objective evidence of efficacy. The 256-channel EEG methodology enables detection of focal sleep-related brain activity changes and potential next-day cognitive impairment that standard polysomnography would miss, informing safer dosing recommendations for clinicians considering cannabinoid-based sleep interventions.
Methodological Considerations:
- Self-reported outcomes — recall and social-desirability bias risk
Abstract: Cannabinoids, particularly Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), have gained popularity as alternative sleep aids; however, their effects on sleep architecture and next-day function remain poorly understood. Here, in a pilot trial, we examined the effects of a single oral dose containing 10 mg THC and 200 mg CBD (THC/CBD) on objective sleep outcomes and next-day alertness using 256-channel high-density EEG in 20 patients with DSM-5 diagnosed insomnia disorder (16 female; mean (SD) age, 46.1 (8.6) years). We showed that THC/CBD decreased total sleep time (-24.5 min, p = 0.05, d = -0.5) with no change in wake after sleep onset (+10.7 min, p > 0.05) compared to placebo. THC/CBD also significantly decreased time spent in REM sleep (-33.9 min, p < 0.001, d = -1.5) and increased latency to REM sleep (+65.6 min, p = 0.008, d = 0.7). High-density EEG analysis revealed regional decreases in gamma activity during N2 sleep, and in delta activity during N3 sleep, and a regional increase in beta and alpha activity during REM sleep. While there was no observed change in next-day objective alertness, a small but significant increase in self-reported sleepiness was noted with THC/CBD (+0.42 points, p = 0.02, d = 0.22). No changes in subjective sleep quality, cognitive performance, or simulated driving performance were observed. These findings suggest that a single dose of cannabinoids, particularly THC, may acutely influence sleep, primarily by suppressing REM sleep, without noticeable next-day impairment (≥ 9 h post-treatment). Australian New Zealand Clinical Trial Registry (ACTRN12619000714189) https://www.anzctr.org.au/.
😴 This pilot study provides useful objective data on acute cannabinoid effects in insomnia, documenting sleep architecture changes via high-density EEG that go beyond subjective patient report. However, the small sample size (n=20), single-dose design, and predominance of female participants limit generalizability, and the study does not appear to address potential tolerance development with repeated use or individual pharmacogenetic variation in cannabinoid metabolism. The specific THC:CBD ratio (10:200 mg) and dosing route tested here may not reflect the heterogeneous cannabis products patients actually use in clinical practice. For providers considering cannabinoids as a trial for insomnia refractory to conventional therapy, this study supports objective investigation of sleep stage effects, but the limited evidence on safety, efficacy trajectories, and next-day cognitive or psychomotor impacts means informed consent conversations should emphasize we are still in early stages of understanding optimal dosing and patient selection criteria.